FR2711670B1
(fr)
|
1993-10-22 |
1996-01-12 |
Pasteur Institut |
Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
|
US6995008B1
(en)
*
|
1994-03-07 |
2006-02-07 |
Merck & Co., Inc. |
Coordinate in vivo gene expression
|
US6727230B1
(en)
|
1994-03-25 |
2004-04-27 |
Coley Pharmaceutical Group, Inc. |
Immune stimulation by phosphorothioate oligonucleotide analogs
|
US5736524A
(en)
*
|
1994-11-14 |
1998-04-07 |
Merck & Co.,. Inc. |
Polynucleotide tuberculosis vaccine
|
FR2732895B1
(fr)
*
|
1995-04-11 |
1997-05-16 |
Pasteur Merieux Serums Vacc |
Utilisation d'un compose amphipathique cationique comme agent de transfection, comme adjuvant de vaccin, ou comme medicament
|
US6458366B1
(en)
|
1995-09-01 |
2002-10-01 |
Corixa Corporation |
Compounds and methods for diagnosis of tuberculosis
|
US6290969B1
(en)
|
1995-09-01 |
2001-09-18 |
Corixa Corporation |
Compounds and methods for immunotherapy and diagnosis of tuberculosis
|
US6338852B1
(en)
|
1995-09-01 |
2002-01-15 |
Corixa Corporation |
Compounds and methods for diagnosis of tuberculosis
|
US6592877B1
(en)
|
1995-09-01 |
2003-07-15 |
Corixa Corporation |
Compounds and methods for immunotherapy and diagnosis of tuberculosis
|
US20070021364A1
(en)
*
|
1995-12-13 |
2007-01-25 |
Hans Herweijer |
Methods for genetic immunization
|
US20020165183A1
(en)
*
|
1999-11-29 |
2002-11-07 |
Hans Herweijer |
Methods for genetic immunization
|
ZA973642B
(en)
*
|
1996-04-26 |
1997-11-25 |
Merck & Co Inc |
DNA vaccine formulations.
|
US5846946A
(en)
*
|
1996-06-14 |
1998-12-08 |
Pasteur Merieux Serums Et Vaccins |
Compositions and methods for administering Borrelia DNA
|
FR2751228B1
(fr)
*
|
1996-07-19 |
1998-11-20 |
Rhone Merieux |
Vaccin polynucleotidique bovin pour voie intradermique
|
FR2751225B1
(fr)
*
|
1996-07-19 |
1998-11-27 |
Rhone Merieux |
Formule de vaccin polynucleotidique aviaire
|
CA2266656A1
(en)
*
|
1996-09-17 |
1998-03-26 |
Chiron Corporation |
Compositions and methods for treating intracellular diseases
|
US6797276B1
(en)
*
|
1996-11-14 |
2004-09-28 |
The United States Of America As Represented By The Secretary Of The Army |
Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
|
US5980898A
(en)
*
|
1996-11-14 |
1999-11-09 |
The United States Of America As Represented By The U.S. Army Medical Research & Material Command |
Adjuvant for transcutaneous immunization
|
US20060002959A1
(en)
*
|
1996-11-14 |
2006-01-05 |
Government Of The United States |
Skin-sctive adjuvants for transcutaneous immuization
|
US20060002949A1
(en)
*
|
1996-11-14 |
2006-01-05 |
Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. |
Transcutaneous immunization without heterologous adjuvant
|
WO1998035029A1
(en)
*
|
1997-02-07 |
1998-08-13 |
Vanderbilt University |
Synthetic genes for recombinant mycobacterium proteins
|
US6261281B1
(en)
*
|
1997-04-03 |
2001-07-17 |
Electrofect As |
Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
|
US20040258703A1
(en)
*
|
1997-11-14 |
2004-12-23 |
The Government Of The Us, As Represented By The Secretary Of The Army |
Skin-active adjuvants for transcutaneous immunization
|
EP1071377A1
(en)
*
|
1998-04-14 |
2001-01-31 |
Merck & Co., Inc. |
Needleless administration of polynucleotide formulations
|
WO2000026248A2
(en)
*
|
1998-11-04 |
2000-05-11 |
Isis Innovation Limited |
Tuberculosis diagnostic test
|
US8197461B1
(en)
|
1998-12-04 |
2012-06-12 |
Durect Corporation |
Controlled release system for delivering therapeutic agents into the inner ear
|
US6465633B1
(en)
|
1998-12-24 |
2002-10-15 |
Corixa Corporation |
Compositions and methods of their use in the treatment, prevention and diagnosis of tuberculosis
|
AU3593200A
(en)
|
1999-02-09 |
2000-08-29 |
Powderject Vaccines, Inc. |
(mycobacterium tuberculosis), immunization
|
JP4932086B2
(ja)
*
|
1999-04-08 |
2012-05-16 |
インターセル ユーエスエイ、インコーポレイテッド |
経皮的免疫のための乾燥製剤
|
US20040258672A1
(en)
*
|
1999-04-15 |
2004-12-23 |
Monash University |
Graft acceptance through manipulation of thymic regeneration
|
US20040265285A1
(en)
*
|
1999-04-15 |
2004-12-30 |
Monash University |
Normalization of defective T cell responsiveness through manipulation of thymic regeneration
|
AUPR074500A0
(en)
*
|
2000-10-13 |
2000-11-09 |
Monash University |
Treatment of t cell disorders
|
US20070274946A1
(en)
*
|
1999-04-15 |
2007-11-29 |
Norwood Immunoloty, Ltd. |
Tolerance to Graft Prior to Thymic Reactivation
|
US20040241842A1
(en)
*
|
1999-04-15 |
2004-12-02 |
Monash University |
Stimulation of thymus for vaccination development
|
US20040259803A1
(en)
*
|
1999-04-15 |
2004-12-23 |
Monash University |
Disease prevention by reactivation of the thymus
|
US20050020524A1
(en)
*
|
1999-04-15 |
2005-01-27 |
Monash University |
Hematopoietic stem cell gene therapy
|
CA2374346C
(en)
*
|
1999-06-28 |
2010-06-22 |
Jordan J. N. Tang |
Inhibitors of memapsin 2 and use thereof
|
US6514948B1
(en)
|
1999-07-02 |
2003-02-04 |
The Regents Of The University Of California |
Method for enhancing an immune response
|
US20050100928A1
(en)
*
|
1999-09-16 |
2005-05-12 |
Zycos Inc., A Delaware Corporation |
Nucleic acids encoding polyepitope polypeptides
|
US6316253B1
(en)
*
|
1999-11-01 |
2001-11-13 |
Chiron Corporation |
Expression vectors, transfection systems, and method of use thereof
|
CA2386341A1
(en)
|
1999-11-18 |
2001-05-25 |
Epimmune Inc. |
Heteroclitic analogs and related methods
|
WO2001045639A2
(en)
*
|
1999-12-22 |
2001-06-28 |
The Ohio State University Research Foundation |
Methods for protecting against lethal infection with bacillus anthracis
|
FR2804028B1
(fr)
*
|
2000-01-21 |
2004-06-04 |
Merial Sas |
Vaccins adn ameliores pour animaux de rente
|
AU2001231245A1
(en)
|
2000-01-31 |
2001-08-07 |
The Regents Of The University Of California |
Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen
|
AU4175101A
(en)
|
2000-02-23 |
2001-09-03 |
Univ California |
Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
|
US20030130217A1
(en)
*
|
2000-02-23 |
2003-07-10 |
Eyal Raz |
Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
|
AU5929101A
(en)
*
|
2000-04-28 |
2001-11-12 |
Us Gov Health & Human Serv |
Improved immunogenicity using a combination of dna and vaccinia virus vector vaccines
|
US6590087B1
(en)
*
|
2000-05-25 |
2003-07-08 |
Johns Hopkins University |
whmD, an essential cell division gene from mycobacteria
|
AU2001271963A1
(en)
*
|
2000-07-10 |
2002-01-21 |
Colorado State University Research Foundation |
Mid-life vaccine and methods for boosting anti-mycobacterial immunity
|
CA2415923C
(en)
|
2000-07-12 |
2011-10-25 |
Agensys, Inc. |
Novel tumor antigen useful in diagnosis and therapy of bladder, ovary, lung and kidney cancers
|
EP2022797A3
(en)
|
2000-08-28 |
2011-11-09 |
Agensys, Inc. |
Nucleic acid and corresponding protein entitled 85P1B3 useful in treatment and detection of cancer
|
US20060088512A1
(en)
*
|
2001-10-15 |
2006-04-27 |
Monash University |
Treatment of T cell disorders
|
EP1455816A4
(en)
|
2000-10-19 |
2007-03-28 |
Epimmune Inc |
HLA CLASS I AND II BINDING PEPTIDES AND THEIR USE
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
US7829084B2
(en)
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
AU2002250071B2
(en)
*
|
2001-02-13 |
2008-02-14 |
Government Of The United States, As Represented By The Secretary Of The Army |
Vaccine for transcutaneous immunization
|
US7491394B2
(en)
|
2001-02-15 |
2009-02-17 |
The Board Of Trustees Of The University Of Illinois |
Cytotoxic factors for modulating cell death
|
US6924358B2
(en)
|
2001-03-05 |
2005-08-02 |
Agensys, Inc. |
121P1F1: a tissue specific protein highly expressed in various cancers
|
US7271240B2
(en)
|
2001-03-14 |
2007-09-18 |
Agensys, Inc. |
125P5C8: a tissue specific protein highly expressed in various cancers
|
US8034791B2
(en)
|
2001-04-06 |
2011-10-11 |
The University Of Chicago |
Activation of Egr-1 promoter by DNA damaging chemotherapeutics
|
JP2004532213A
(ja)
*
|
2001-04-06 |
2004-10-21 |
ザ ユニヴァーシティ オヴ シカゴ |
Egr−1プロモーター活性の化学療法誘導
|
US20040242523A1
(en)
*
|
2003-03-06 |
2004-12-02 |
Ana-Farber Cancer Institue And The Univiersity Of Chicago |
Chemo-inducible cancer gene therapy
|
US7736654B2
(en)
|
2001-04-10 |
2010-06-15 |
Agensys, Inc. |
Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
|
US20030191073A1
(en)
|
2001-11-07 |
2003-10-09 |
Challita-Eid Pia M. |
Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
|
US7013940B2
(en)
*
|
2001-04-19 |
2006-03-21 |
Michelin Recherche Et Technique S.A. |
Device for attenuating cavity noise in a tire and wheel
|
US7452705B2
(en)
|
2001-05-22 |
2008-11-18 |
The University Of Chicago |
N4 virion single-stranded DNA dependent RNA polymerase
|
EP1497654A4
(en)
*
|
2001-08-13 |
2006-06-07 |
Chen Swey Shen Alex |
IMMUNOGLOBULIN E VACCINES AND METHODS OF USE
|
ES2532757T3
(es)
|
2001-09-06 |
2015-03-31 |
Agensys, Inc. |
Ácido nucleico y proteína correspondiente denominados STEAP-1 útiles en el tratamiento y la detección de cáncer
|
MXPA04003944A
(es)
*
|
2001-10-26 |
2004-07-08 |
Baylor College Medicine |
Una composicion y metodo para alterar la masa corporal fina y propiedades oseas en un sujeto.
|
AU2002357143B2
(en)
|
2001-12-11 |
2009-07-30 |
Advisys, Inc. |
Growth hormone releasing hormone supplementation for treating chronically ill subjects
|
US20040052773A1
(en)
*
|
2002-01-18 |
2004-03-18 |
Inovio As |
Production of multi-chain protein from muscle
|
EP3415625A1
(en)
*
|
2002-02-01 |
2018-12-19 |
Life Technologies Corporation |
Double-stranded oligonucleotides
|
US20030166282A1
(en)
|
2002-02-01 |
2003-09-04 |
David Brown |
High potency siRNAS for reducing the expression of target genes
|
US20030199012A1
(en)
*
|
2002-02-01 |
2003-10-23 |
Ho John L. |
Compositions and methods for treatment of infectious and inflammatory diseases
|
US20060009409A1
(en)
|
2002-02-01 |
2006-01-12 |
Woolf Tod M |
Double-stranded oligonucleotides
|
US20050267025A1
(en)
*
|
2002-02-01 |
2005-12-01 |
Ho John L |
Compositions and methods for treatment of infectious and inflammatory diseases
|
US20050222060A1
(en)
*
|
2002-03-15 |
2005-10-06 |
Bot Adrian L |
Compositions and methods to initiate or enhance antibody and major-histocompatibility class I or class II-restricted t cell responses by using immunomodulatory, non-coding rna motifs
|
US20070037769A1
(en)
*
|
2003-03-14 |
2007-02-15 |
Multicell Immunotherapeutics, Inc. |
Compositions and methods to treat and control tumors by loading antigen presenting cells
|
EP2258712A3
(en)
|
2002-03-15 |
2011-05-04 |
Multicell Immunotherapeutics, Inc. |
Compositions and Methods to Initiate or Enhance Antibody and Major-histocompatibility Class I or Class II-restricted T Cell Responses by Using Immunomodulatory, Non-coding RNA Motifs
|
US7078037B2
(en)
*
|
2002-04-19 |
2006-07-18 |
The Arizona Board Of Regents On Behalf Of The University Of Arizona |
Peptides and DNA encoding the peptides useful for immunizations against Coccidioides spp. infections
|
WO2004041997A2
(en)
*
|
2002-05-01 |
2004-05-21 |
National Institutes Of Health |
Immunotherapy regimens in hiv-infected patients
|
JP4643255B2
(ja)
|
2002-06-10 |
2011-03-02 |
バクシネックス インコーポレーティッド |
乳癌および膀胱癌において差次的に発現される遺伝子ならびにコードされるポリペプチド
|
US20090110702A1
(en)
*
|
2002-07-12 |
2009-04-30 |
The Johns Hopkins University |
Mesothelin Vaccines and Model Systems and Control of Tumors
|
US9200036B2
(en)
|
2002-07-12 |
2015-12-01 |
The Johns Hopkins University |
Mesothelin vaccines and model systems
|
JP2006521090A
(ja)
*
|
2002-07-12 |
2006-09-21 |
ザ ジョンズ ホプキンス ユニバーシティー |
メゾテリンワクチンおよびモデルシステム
|
AU2003304195B8
(en)
|
2002-07-15 |
2008-08-28 |
Board Of Regents, The University Of Texas System |
Combinatorial protein library screening by periplasmic expression
|
US20040029275A1
(en)
*
|
2002-08-10 |
2004-02-12 |
David Brown |
Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs
|
KR20120002613A
(ko)
|
2002-08-12 |
2012-01-06 |
제네렉스, 인코포레이티드 |
폭스바이러스 및 암과 관련된 방법 및 조성물
|
AU2003243151A1
(en)
|
2002-08-16 |
2004-03-03 |
Agensys, Inc. |
Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
|
ATE465753T1
(de)
*
|
2002-10-21 |
2010-05-15 |
Eisai Inc |
Zusammensetzungen und verfahren zurbehandlung von krankheiten, die durch das humane papillomavirus vermitteltwerden
|
JP2006508163A
(ja)
|
2002-11-27 |
2006-03-09 |
アジェンシス, インコーポレイテッド |
癌の処置および検出において有用な24p4c12と称される、核酸および対応タンパク質
|
EP1903056A3
(en)
|
2002-12-10 |
2008-05-07 |
Idm Pharma, Inc. |
HLA-A1, -A2 -A3, -A24, -B7, and -B44 binding peptides comprising tumor associated antigen epitopes, and compositions thereof
|
AU2004210975B2
(en)
|
2003-02-10 |
2008-04-10 |
Agensys, Inc. |
Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers
|
US7262027B2
(en)
*
|
2003-03-14 |
2007-08-28 |
Medical College Of Ohio |
Polypeptide and DNA immunization against Coccidioides spp. infections
|
AU2004225480A1
(en)
*
|
2003-03-26 |
2004-10-14 |
Multicell Immunotherapeutics, Inc. |
Selected RNA motifs to include cell death and/or apoptosis
|
TW200424214A
(en)
*
|
2003-04-21 |
2004-11-16 |
Advisys Inc |
Plasmid mediated GHRH supplementation for renal failures
|
WO2004098497A2
(en)
*
|
2003-04-28 |
2004-11-18 |
Genencor International, Inc. |
Cd4+ human papillomavirus (hpv) epitopes
|
NZ572940A
(en)
|
2003-05-30 |
2010-04-30 |
Agensys Inc |
Prostate stem cell antigen (PSCA) variants and subsequences thereof
|
WO2004110482A1
(en)
*
|
2003-06-13 |
2004-12-23 |
Isis Innovation Limited |
Improved vaccines
|
US20070224615A1
(en)
*
|
2003-07-09 |
2007-09-27 |
Invitrogen Corporation |
Methods for assaying protein-protein interactions
|
US7049076B2
(en)
|
2003-07-09 |
2006-05-23 |
Sentigen Biosciences, Inc. |
Method for assaying protein—protein interaction
|
EP1660686B1
(en)
*
|
2003-09-05 |
2012-05-09 |
Genencor International, Inc. |
Hpv cd8+ t-cell epitopes
|
US20080279812A1
(en)
*
|
2003-12-05 |
2008-11-13 |
Norwood Immunology, Ltd. |
Disease Prevention and Vaccination Prior to Thymic Reactivation
|
CA2555013C
(en)
*
|
2004-02-11 |
2013-10-15 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. |
Carcinoembryonic antigen fusions and uses thereof
|
US20070287150A1
(en)
*
|
2004-03-18 |
2007-12-13 |
Rohrschneider Larry R |
Methods And Compositions Involving S-Ship Promoter Regions
|
WO2005118864A2
(en)
|
2004-05-28 |
2005-12-15 |
Agensys, Inc. |
Antibodies and related molecules that bind to psca proteins
|
WO2006017279A2
(en)
*
|
2004-07-12 |
2006-02-16 |
Board Of Regents, The University Of Texas System |
Methods and compositions related to identifying protein-protein interactions
|
US7572600B2
(en)
|
2004-08-04 |
2009-08-11 |
Chemocentryx, Inc. |
Enzymatic activities in chemokine-mediated inflammation
|
WO2006137941A2
(en)
|
2004-11-12 |
2006-12-28 |
Ambion, Inc. |
Methods and compositions involving mirna and mirna inhibitor molecules
|
SG159554A1
(en)
|
2004-11-16 |
2010-03-30 |
Crucell Holland Bv |
Multivalent vaccines comprising recombinant viral vectors
|
JP5461776B2
(ja)
*
|
2004-12-01 |
2014-04-02 |
エーラス グローバル ティービー ワクチン ファウンデーション |
マイコバクテリウムのエレクトロポレーションおよびマイコバクテリア中における抗原類の過剰発現
|
AU2006212885A1
(en)
*
|
2005-02-11 |
2006-08-17 |
Merck & Co., Inc. |
Adenovirus serotype 26 vectors, nucleic acid and viruses produced thereby
|
DK2325306T3
(en)
|
2005-02-25 |
2014-03-03 |
Oncotherapy Science Inc |
Peptide vaccines against lung cancers expressing TTK, URLC10 or KOC1 polypeptide
|
EP2289533B1
(en)
|
2005-02-28 |
2013-09-18 |
Oncotherapy Science, Inc. |
Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides
|
RU2413735C2
(ru)
|
2005-03-31 |
2011-03-10 |
Эдженсис, Инк. |
Антитела и родственные молекулы, связывающиеся с белками 161p2f10b
|
HUE026303T2
(hu)
|
2005-07-25 |
2016-06-28 |
Emergent Product Dev Seattle |
B-sejt csökkentés CD37-specifikus és CD20-specifikus kapcsoló molekulák alkalmazásával
|
US8674059B2
(en)
|
2005-07-27 |
2014-03-18 |
Oncotherapy Science, Inc. |
Colon cancer related gene TOM34
|
CA2618508A1
(en)
*
|
2005-08-10 |
2007-02-22 |
Oklahoma Medical Research Foundation |
Truncated memapsin 2 for use for treating alzheimer's disease
|
US8980246B2
(en)
|
2005-09-07 |
2015-03-17 |
Sillajen Biotherapeutics, Inc. |
Oncolytic vaccinia virus cancer therapy
|
US9180149B2
(en)
*
|
2005-09-07 |
2015-11-10 |
Sillajen Biotherapeutics, Inc. |
Systemic treatment of metastatic and/or systemically-disseminated cancers using GM-CSF-expressing poxviruses
|
US7919258B2
(en)
*
|
2005-10-07 |
2011-04-05 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Rapid tuberculosis detection method
|
AU2007281934B2
(en)
|
2006-01-18 |
2012-11-15 |
University Of Chicago |
Compositions and methods related to Staphylococcal bacterium proteins
|
BRPI0708865A8
(pt)
*
|
2006-03-14 |
2019-01-22 |
Univ Oregon Health & Science |
métodos para produzir uma resposta imune à tuberculose
|
GB0605474D0
(en)
*
|
2006-03-17 |
2006-04-26 |
Isis Innovation |
Clinical correlates
|
EP2418223A3
(en)
|
2006-06-12 |
2013-01-16 |
Emergent Product Development Seattle, LLC |
Single-chain multivalent binding proteins with effector function
|
ATE543097T1
(de)
|
2006-07-27 |
2012-02-15 |
Univ Maryland |
Zellulärer rezeptor für antiproliferativen faktor
|
US8481023B2
(en)
|
2006-09-15 |
2013-07-09 |
Ottawa Hospital Research Institute |
Oncolytic rhabdovirus
|
CN102850435B
(zh)
|
2006-10-17 |
2016-02-17 |
肿瘤疗法科学股份有限公司 |
用于表达mphosph1或depdc1多肽的癌症的肽疫苗
|
EP2522735A3
(en)
*
|
2006-10-20 |
2013-02-13 |
Arizona Board Of Regents For And On Behalf Arizona State University |
Modified cyanobacteria
|
WO2008067547A2
(en)
|
2006-11-30 |
2008-06-05 |
Research Development Foundation |
Improved immunoglobulin libraries
|
TWI596109B
(zh)
|
2007-02-21 |
2017-08-21 |
腫瘤療法 科學股份有限公司 |
表現腫瘤相關抗原之癌症的胜肽疫苗
|
KR20080084528A
(ko)
|
2007-03-15 |
2008-09-19 |
제네렉스 바이오테라퓨틱스 인크. |
종양살상형 백시니아 바이러스 암 치료
|
TWI434853B
(zh)
|
2007-04-11 |
2014-04-21 |
Oncotherapy Science Inc |
腫瘤血管內皮標誌8胜肽及包含此胜肽之疫苗
|
EP2155789B1
(en)
|
2007-05-01 |
2013-07-24 |
Research Development Foundation |
Immunoglobulin fc libraries
|
BRPI0814060A2
(pt)
*
|
2007-07-06 |
2015-01-06 |
Trubion Pharmaceuticals Inc |
Peptídeos ligantes tendo um domínio de ligação específico disposto em c-terminal
|
JP5658564B2
(ja)
|
2007-08-31 |
2015-01-28 |
ザ・ユニバーシティ・オブ・シカゴThe University Of Chicago |
ブドウ球菌肺疾患および状態に対する免疫に関連した方法および組成物
|
CN102066410B
(zh)
|
2007-11-01 |
2017-01-18 |
梅约医学教育与研究基金会 |
Hla‑dr结合肽和它们的应用
|
US9605035B2
(en)
|
2008-01-10 |
2017-03-28 |
Research Development Foundation |
Vaccines and diagnostics for the ehrlichioses
|
NZ586746A
(en)
*
|
2008-01-23 |
2012-07-27 |
Righospitalet |
Classification of individuals suffering from cardiovascular diseases according to survival prognoses as found by measuring the levels of biomarker ykl-40
|
PL2245464T3
(pl)
|
2008-01-25 |
2017-08-31 |
Multivir Inc. |
Biomarkery p53
|
WO2009117439A2
(en)
|
2008-03-17 |
2009-09-24 |
The Scripps Research Institute |
Combined chemical and genetic approaches for generation of induced pluripotent stem cells
|
WO2009117134A2
(en)
*
|
2008-03-21 |
2009-09-24 |
National Institutes Of Health |
Aerosolized genetic vaccines and methods of use
|
DK2132228T3
(da)
*
|
2008-04-11 |
2011-10-10 |
Emergent Product Dev Seattle |
CD37-immunterapeutisk middel og kombination med bifunktionelt kemoterapeutisk middel deraf
|
US9017660B2
(en)
|
2009-11-11 |
2015-04-28 |
Advaxis, Inc. |
Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
|
US9650639B2
(en)
|
2008-05-19 |
2017-05-16 |
Advaxis, Inc. |
Dual delivery system for heterologous antigens
|
EP2288379A4
(en)
|
2008-05-19 |
2012-08-08 |
Advaxis |
DOUBLE RELEASE SYSTEM FOR HETEROLOGIST ANTIGENE
|
AU2009256202B2
(en)
|
2008-06-04 |
2014-07-03 |
FUJIFILM Cellular Dynamics, Inc. |
Methods for the production of IPS cells using non-viral approach
|
WO2010010577A1
(en)
*
|
2008-07-25 |
2010-01-28 |
Department Of Biotechnology |
Constructing a dna chimera for vaccine development against leishmaniasis and tuberculosis
|
AU2009282133B2
(en)
|
2008-08-12 |
2015-12-10 |
FUJIFILM Cellular Dynamics, Inc. |
Methods for the Production of IPS Cells
|
CA2734325A1
(en)
|
2008-08-18 |
2010-02-25 |
University Of Maryland, Baltimore |
Derivatives of apf and methods of use
|
US8512944B2
(en)
|
2008-08-27 |
2013-08-20 |
Oncotherapy Science, Inc. |
PRMT1 for target genes of cancer therapy and diagnosis
|
BRPI0920041A2
(pt)
|
2008-10-06 |
2017-06-27 |
Univ Chicago |
composições e processos relacionados às proteínas eap, emp e/ou adsa bacterianas
|
EP2352747A1
(en)
*
|
2008-10-23 |
2011-08-10 |
Intervet International BV |
Lawsonia intracellularis vaccines
|
TWI539160B
(zh)
|
2008-12-05 |
2016-06-21 |
腫瘤療法 科學股份有限公司 |
Wdrpuh抗原決定位胜肽以及含此胜肽之疫苗
|
US9084781B2
(en)
|
2008-12-10 |
2015-07-21 |
Novartis Ag |
MEK mutations conferring resistance to MEK inhibitors
|
SG172160A1
(en)
|
2008-12-17 |
2011-07-28 |
Scripps Research Inst |
Generation and maintenance of stem cells
|
EP2379720B1
(en)
|
2009-01-20 |
2016-08-17 |
Alona Zilberberg |
Mir-21 promoter driven targeted cancer therapy
|
TWI469791B
(zh)
|
2009-02-18 |
2015-01-21 |
Oncotherapy Science Inc |
Foxm1胜肽以及含此胜肽之疫苗
|
WO2010106770A1
(en)
|
2009-03-18 |
2010-09-23 |
Oncotherapy Science, Inc. |
Neil3 peptides and vaccines including the same
|
BRPI1010307B1
(pt)
|
2009-04-03 |
2021-07-27 |
University Of Chicago |
Polipeptídeos variantes de proteína a (spa), composição imunogênica compreendendo os mesmos, vacina, método de produção da referida vacina, bem como uso dos referidos polipeptídeos
|
EP2424885B1
(en)
|
2009-04-28 |
2016-03-23 |
Vanderbilt University |
Compositions and methods for the treatment of disorders involving epithelial cell apoptosis
|
TWI507204B
(zh)
|
2009-05-26 |
2015-11-11 |
Oncotherapy Science Inc |
Cdc45l胜肽與含此胜肽之疫苗
|
CA2952805C
(en)
|
2009-06-05 |
2021-06-01 |
Cellular Dynamics International, Inc. |
Reprogramming t cells and hematopoietic cells
|
EP2470653A1
(en)
|
2009-08-26 |
2012-07-04 |
Research Development Foundation |
Methods for creating antibody libraries
|
EP3409119B1
(en)
|
2009-09-14 |
2020-08-12 |
SillaJen Biotherapeutics, Inc. |
Oncolytic vaccinia virus combination cancer therapy
|
WO2011038290A2
(en)
|
2009-09-25 |
2011-03-31 |
The U. S. A., As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 and their use
|
CA2775720A1
(en)
*
|
2009-09-30 |
2011-04-07 |
Saint Louis University |
Peptides for inducing heterosubtypic influenza t cell responses
|
CN102741394B
(zh)
|
2009-10-16 |
2016-05-04 |
斯克里普斯研究所 |
多能细胞的诱导
|
US10016617B2
(en)
|
2009-11-11 |
2018-07-10 |
The Trustees Of The University Of Pennsylvania |
Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
|
CA2836117C
(en)
|
2009-12-10 |
2017-08-15 |
Ottawa Hospital Research Institute |
Oncolytic rhabdovirus
|
TW201136604A
(en)
|
2009-12-14 |
2011-11-01 |
Oncotherapy Science Inc |
TMEM22 peptides and vaccines including the same
|
WO2011100508A2
(en)
|
2010-02-12 |
2011-08-18 |
Arizona Board Of Regents For And On Behalf Of Arizona State University |
Methods and compositions related to glycoprotein-immunoglobulin fusions
|
WO2011106298A1
(en)
|
2010-02-25 |
2011-09-01 |
Dana-Farber Cancer Institute, Inc. |
Braf mutations conferring resistance to braf inhibitors
|
WO2011106705A2
(en)
|
2010-02-26 |
2011-09-01 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Dna-protein vaccination protocols
|
ES2631458T3
(es)
|
2010-03-04 |
2017-08-31 |
Interna Technologies B.V. |
Molécula de ARNmi definida por su fuente y sus usos terapéuticos en el cáncer asociado a la EMT
|
AU2011225577B2
(en)
|
2010-03-11 |
2017-01-19 |
Oncotherapy Science, Inc. |
HJURP peptides and vaccines including the same
|
CN105176930B
(zh)
|
2010-03-31 |
2021-05-04 |
斯克里普斯研究所 |
重编程细胞
|
TW201627003A
(zh)
|
2010-04-02 |
2016-08-01 |
腫瘤療法 科學股份有限公司 |
Ect2胜肽及含此胜肽之疫苗
|
JP2013523818A
(ja)
|
2010-04-05 |
2013-06-17 |
ザ・ユニバーシティー・オブ・シカゴ |
免疫反応のエンハンサーとしてのプロテインA(SpA)抗体に関連する組成物および方法
|
WO2011126976A1
(en)
|
2010-04-07 |
2011-10-13 |
Vanderbilt University |
Reovirus vaccines and methods of use therefor
|
WO2011133512A1
(en)
|
2010-04-19 |
2011-10-27 |
Research Development Foundation |
Rtef-1 variants and uses thereof
|
JP5908466B2
(ja)
|
2010-06-09 |
2016-04-26 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
Raf及びmek阻害剤に対する耐性を与えるmek1変異
|
WO2011159726A2
(en)
|
2010-06-14 |
2011-12-22 |
The Scripps Research Institute |
Reprogramming of cells to a new fate
|
US20110312001A1
(en)
|
2010-06-15 |
2011-12-22 |
Emile Nuwaysir |
Compendium of ready-built stem cell models for interrogation of biological response
|
WO2011159684A2
(en)
|
2010-06-15 |
2011-12-22 |
Cellular Dynamics International, Inc. |
Generation of induced pluripotent stem cells from small volumes of peripheral blood
|
ES2655701T3
(es)
|
2010-07-02 |
2018-02-21 |
The University Of Chicago |
Composiciones y métodos relacionados con variantes de la proteína A (SpA)
|
NZ719520A
(en)
|
2010-07-06 |
2017-07-28 |
Int Tech Bv |
Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
|
US8785192B2
(en)
|
2010-07-07 |
2014-07-22 |
Cellular Dynamics International, Inc. |
Endothelial cell production by programming
|
JP5936218B2
(ja)
|
2010-08-04 |
2016-06-22 |
セルラー ダイナミクス インターナショナル, インコーポレイテッド |
不死化b細胞のリプログラミング
|
US9095540B2
(en)
|
2010-09-09 |
2015-08-04 |
The University Of Chicago |
Methods and compositions involving protective staphylococcal antigens
|
WO2012040295A2
(en)
|
2010-09-22 |
2012-03-29 |
The Regents Of The University Of Colorado |
Therapeutic applications of smad7
|
WO2012138377A2
(en)
|
2010-10-01 |
2012-10-11 |
Trustees Of The University Of Pennsylvania |
The use of listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals
|
WO2012044979A2
(en)
|
2010-10-01 |
2012-04-05 |
The Goverment Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Manipulation of stem cell function by p53 isoforms
|
CN103380212B
(zh)
|
2010-12-22 |
2017-04-05 |
菲特治疗公司 |
用于单细胞分选与增强ipsc重新编程的细胞培养平台
|
KR101942237B1
(ko)
|
2011-01-04 |
2019-01-25 |
신라젠(주) |
종양 항원에 대한 항체의 생산 및 종양용해 우두 바이러스의 투여에 의한 종양 특이적 보체 의존적 세포독성의 생산
|
EP2474617A1
(en)
|
2011-01-11 |
2012-07-11 |
InteRNA Technologies BV |
Mir for treating neo-angiogenesis
|
RU2539035C2
(ru)
*
|
2011-01-13 |
2015-01-10 |
Амир Закиевич Максютов |
Профилактическая или терапевтическая полиэпитопная противотуберкулезная вакцинная конструкция, обеспечивающая индукцию клеточного иммунного ответа cd4+ или cd8+ т-лимфоцитов
|
AU2012214643B2
(en)
|
2011-02-07 |
2016-12-15 |
Research Development Foundation |
Engineered immunoglobulin Fc polypeptides
|
US9574179B2
(en)
|
2011-02-08 |
2017-02-21 |
Cellular Dynamics International, Inc. |
Hematopoietic precursor cell production by programming
|
EP2683400A4
(en)
|
2011-03-11 |
2014-09-17 |
Advaxis |
ADJUVANZIA ON LISTERIA BASE
|
EP2694534B1
(en)
|
2011-04-08 |
2018-06-20 |
Evaxion Biotech ApS |
Proteins and nucleic acids useful in vaccines targeting staphylococcus aureus
|
US8945588B2
(en)
|
2011-05-06 |
2015-02-03 |
The University Of Chicago |
Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
|
US9822379B2
(en)
|
2011-05-19 |
2017-11-21 |
Fundación Pública Andaluza Progreso Y Salud |
Highly inducible dual-promoter lentiviral TET-ON system
|
WO2012167382A1
(en)
|
2011-06-08 |
2012-12-13 |
Children's Hospital Of Eastern Ontario Research Institute Inc. |
Compositions and methods for glioblastoma treatment
|
CA2841165A1
(en)
|
2011-07-11 |
2013-01-17 |
Cellular Dynamics International, Inc. |
Methods for cell reprogramming and genome engineering
|
WO2013018690A1
(ja)
|
2011-07-29 |
2013-02-07 |
国立大学法人徳島大学 |
Erap1由来ペプチド及びその使用
|
KR102015648B1
(ko)
|
2011-08-12 |
2019-08-28 |
온코세라피 사이언스 가부시키가이샤 |
Mphosph1 펩티드 및 이를 포함한 백신
|
CN103906535B
(zh)
|
2011-08-15 |
2017-07-14 |
芝加哥大学 |
与葡萄球菌蛋白a的抗体相关的组合物和方法
|
US20130101664A1
(en)
|
2011-08-18 |
2013-04-25 |
Donald W. Kufe |
Muc1 ligand traps for use in treating cancers
|
JP2013046596A
(ja)
*
|
2011-08-29 |
2013-03-07 |
Alpha-Nano-Medica Co Ltd |
新規な複合体、それを含有する医薬及び癌の治療方法
|
EP2766388A1
(en)
|
2011-10-12 |
2014-08-20 |
Møller, Niels Iversen |
Peptides derived from campylobacter jejuni and their use in vaccination
|
UA114298C2
(uk)
|
2011-10-28 |
2017-05-25 |
Онкотерапі Саєнс, Інк. |
Пептид торк та вакцина, що його містить
|
EP3369818B1
(en)
|
2011-12-22 |
2021-06-09 |
InteRNA Technologies B.V. |
Mirna for treating head and neck cancer
|
SG11201405605VA
(en)
|
2012-03-12 |
2014-10-30 |
Advaxis Inc |
SUPPRESSOR CELL FUNCTION INHIBITION FOLLOWING <i>LISTERIA</i> VACCINE TREATMENT
|
EP2841101B1
(en)
|
2012-04-26 |
2019-08-07 |
University Of Chicago |
Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease
|
CN104768572B
(zh)
|
2012-04-26 |
2021-08-24 |
芝加哥大学 |
葡萄球菌凝固酶抗原及其使用方法
|
JP6259983B2
(ja)
|
2012-07-10 |
2018-01-17 |
オンコセラピー・サイエンス株式会社 |
Th1細胞のKIF20Aエピトープペプチドおよびこれを含有するワクチン
|
US9644010B2
(en)
|
2012-07-10 |
2017-05-09 |
Oncotherapy Science, Inc. |
LY6K epitope peptides for TH1 cells and vaccines containing the same
|
WO2014041784A1
(en)
|
2012-09-11 |
2014-03-20 |
Oncotherapy Science, Inc. |
Ube2t peptides and vaccines containing the same
|
US9890216B2
(en)
|
2012-10-23 |
2018-02-13 |
Board Of Regents, The University Of Texas System |
Antibodies with engineered IgG Fc domains
|
EP2917348A1
(en)
|
2012-11-06 |
2015-09-16 |
InteRNA Technologies B.V. |
Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated b-raf pathway
|
US10125373B2
(en)
|
2013-01-22 |
2018-11-13 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Geminiviral vector for expression of rituximab
|
WO2014130706A1
(en)
|
2013-02-20 |
2014-08-28 |
Regeneron Pharmaceuticals, Inc. |
Genetic modification of rats
|
RU2684211C2
(ru)
|
2013-02-21 |
2019-04-04 |
Тёрнстоун Лимитед Партнершип |
Композиция вакцины
|
AU2014218807A1
(en)
|
2013-02-22 |
2015-09-03 |
Cellular Dynamics International, Inc. |
Hepatocyte production via forward programming by combined genetic and chemical engineering
|
EP2961386B1
(en)
|
2013-02-28 |
2019-07-10 |
The General Hospital Corporation |
Mirna profiling compositions and methods of use
|
EP2964774B1
(en)
|
2013-03-08 |
2020-05-06 |
The Regents of The University of Colorado, A Body Corporate |
Ptd-smad7 therapeutics
|
TWI658049B
(zh)
|
2013-03-12 |
2019-05-01 |
腫瘤療法 科學股份有限公司 |
Kntc2胜肽及含此胜肽之疫苗
|
US9809801B2
(en)
*
|
2013-03-15 |
2017-11-07 |
Université De Genève |
Anti-mycobacterial vaccines
|
CN111905099A
(zh)
|
2013-03-27 |
2020-11-10 |
免疫疫苗技术有限公司 |
用于改善存活蛋白疫苗在癌症治疗中的功效的方法
|
RU2520078C1
(ru)
*
|
2013-04-25 |
2014-06-20 |
Федеральное государственное бюджетное учреждение "Научно-исследовательский институт эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации (ФГБУ "НИИЭМ им. Н.Ф. Гамалеи" Минздрава России) |
СПОСОБ ПОЛУЧЕНИЯ ИММУНОГЕННОЙ КОМПОЗИЦИИ НА ОСНОВЕ ГИБРИДНОГО БЕЛКА Ag85A-DBD И ДЕКСТРАНА, РЕКОМБИНАНТНАЯ ПЛАЗМИДА pAg85A-DBD, ШТАММ Escherichia coli [pREP4, pAg85A-DBD], ХИМЕРНЫЙ БЕЛОК Ag85A-DBD
|
EP3043825A4
(en)
|
2013-09-09 |
2017-05-03 |
Figene, LLC |
Gene therapy for the regeneration of chondrocytes or cartilage type cells
|
EP3065706A4
(en)
|
2013-11-08 |
2017-11-29 |
Baylor Research Institute |
Nuclear localization of glp-1 stimulates myocardial regeneration and reverses heart failure
|
EP3065775B1
(en)
|
2013-11-08 |
2020-09-30 |
The Board of Regents of the University of Texas System |
Vh4 antibodies against gray matter neuron and astrocyte
|
WO2015082536A1
(en)
|
2013-12-03 |
2015-06-11 |
Evaxion Biotech Aps |
Proteins and nucleic acids useful in vaccines targeting staphylococcus aureus
|
WO2015116753A1
(en)
|
2014-01-29 |
2015-08-06 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against the muc1-c/extracellular domain (muc1-c/ecd)
|
US10214741B2
(en)
|
2014-02-14 |
2019-02-26 |
University Of Utah Research Foundation |
Methods and compositions for inhibiting retinopathy of prematurity
|
US20170037091A1
(en)
|
2014-02-25 |
2017-02-09 |
Research Development Foundation |
Sty peptides for inhibition of angiogenesis
|
KR102460549B1
(ko)
|
2014-03-04 |
2022-10-28 |
페이트 세러퓨틱스, 인코포레이티드 |
개선된 재프로그래밍 방법 및 세포 배양 플랫폼
|
WO2015164228A1
(en)
|
2014-04-21 |
2015-10-29 |
Cellular Dynamics International, Inc. |
Hepatocyte production via forward programming by combined genetic and chemical engineering
|
ES2856834T3
(es)
|
2014-08-04 |
2021-09-28 |
Oncotherapy Science Inc |
Péptido derivado de URLC10 y vacuna que contiene el mismo
|
SG11201700839SA
(en)
|
2014-08-04 |
2017-03-30 |
Oncotherapy Science Inc |
Cdca1-derived peptide and vaccine containing same
|
EP4353321A3
(en)
|
2014-08-04 |
2024-07-10 |
OncoTherapy Science, Inc. |
Koc1-derived peptide and vaccine including same
|
US20180363070A9
(en)
|
2014-08-12 |
2018-12-20 |
Univ Wayne State |
Systems and methods to detect stem cell stress and uses thereof
|
EP3777883A1
(en)
|
2014-11-13 |
2021-02-17 |
Evaxion Biotech ApS |
Peptides derived from acinetobacter baumannii and their use in vaccination
|
EP3242883A4
(en)
|
2015-01-06 |
2018-10-17 |
ImmunoVaccine Technologies Inc. |
Lipid a mimics, methods of preparation, and uses thereof
|
EP3244918A2
(en)
|
2015-01-12 |
2017-11-22 |
Evaxion Biotech ApS |
Proteins and nucleic acids useful in vaccines targeting klebsiella pneumoniae
|
US20180002656A1
(en)
|
2015-01-28 |
2018-01-04 |
Sabic Global Technologies B.V. |
Methods and compositions for high-efficiency production of biofuel and/or biomass
|
WO2016130516A1
(en)
|
2015-02-09 |
2016-08-18 |
Research Development Foundation |
Engineered immunoglobulin fc polypeptides displaying improved complement activation
|
EP3259346A4
(en)
|
2015-02-20 |
2018-07-11 |
Baylor College of Medicine |
P63 inactivation for the treatment of heart failure
|
EP3294755B1
(en)
|
2015-05-13 |
2023-08-23 |
The United States of America as represented by the Secretary of the Department of Health and Human Services |
Methods and compositions for inducing an immune response using conserved element constructs
|
WO2016196366A1
(en)
|
2015-05-29 |
2016-12-08 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Extension of replicative lifespan in diseases of premature aging using p53 isoforms
|
EP4116316A1
(en)
|
2015-07-04 |
2023-01-11 |
Evaxion Biotech A/S |
Proteins and nucleic acids useful in vaccines targeting pseudomonas aeruginosa
|
US10526408B2
(en)
|
2015-08-28 |
2020-01-07 |
Research Development Foundation |
Engineered antibody FC variants
|
CN108367004B
(zh)
|
2015-09-21 |
2022-09-13 |
阿帕特夫研究和发展有限公司 |
Cd3结合多肽
|
BR112018005581A2
(pt)
|
2015-10-08 |
2018-10-16 |
Oncotherapy Science, Inc. |
peptídeo derivado de foxm1 e vacina incluindo o mesmo
|
EP3362570A4
(en)
|
2015-10-16 |
2019-03-20 |
Fate Therapeutics, Inc. |
PLATFORM FOR INDUCTION AND MAINTENANCE OF PLURIPOTENCE IN THE FUNDAMENTAL STATE
|
ES2862676T3
(es)
|
2015-10-20 |
2021-10-07 |
Fujifilm Cellular Dynamics Inc |
Producción de células precursoras hematopoyéticas multilinaje mediante programación genética
|
AU2016343682A1
(en)
|
2015-10-30 |
2018-06-14 |
The Regents Of The University Of California |
Methods of generating T-cells from stem cells and immunotherapeutic methods using the T-cells
|
US11594135B2
(en)
|
2015-11-02 |
2023-02-28 |
Memgen, Inc. |
Methods of CD40 activation and immune checkpoint blockade
|
AU2016349632A1
(en)
|
2015-11-07 |
2018-05-24 |
Multivir Inc. |
Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
|
CA3004438A1
(en)
|
2015-11-09 |
2017-05-18 |
The Children's Hospital Of Philadelphia |
Glypican 2 as a cancer marker and therapeutic target
|
EP3419654B1
(en)
|
2016-02-22 |
2022-04-27 |
Evaxion Biotech A/S |
Proteins and nucleic acids useful in vaccines targeting staphylococcus aureus
|
CA3019635A1
(en)
|
2016-03-31 |
2017-10-05 |
Baylor Research Institute |
Angiopoietin-like protein 8 (angptl8)
|
WO2017216384A1
(en)
|
2016-06-17 |
2017-12-21 |
Evaxion Biotech Aps |
Vaccination targeting ichthyophthirius multifiliis
|
CA3028827A1
(en)
*
|
2016-06-22 |
2017-12-28 |
Aeras |
Recombinant cytomegalovirus vectors as vaccines for tuberculosis
|
WO2017220787A1
(en)
|
2016-06-24 |
2017-12-28 |
Evaxion Biotech Aps |
Vaccines against aearomonas salmonicida infection
|
US20180030478A1
(en)
|
2016-07-01 |
2018-02-01 |
Research Development Foundation |
Elimination of proliferating cells from stem cell-derived grafts
|
EP3889167A1
(en)
|
2016-07-22 |
2021-10-06 |
Evaxion Biotech ApS |
Chimeric proteins for inducing immunity towards infection with s. aureus
|
US9963498B2
(en)
|
2016-08-18 |
2018-05-08 |
Wisconsin Alumni Research Foundation |
Peptides that inhibit syndecan-1 activation of VLA-4 and IGF-1R
|
US11701384B2
(en)
|
2016-09-02 |
2023-07-18 |
The Regents Of The University Of California |
Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments
|
US10961505B2
(en)
|
2016-10-05 |
2021-03-30 |
FUJIFILM Cellular Dynamics, Inc. |
Generating mature lineages from induced pluripotent stem cells with MECP2 disruption
|
JP7212615B2
(ja)
|
2016-10-05 |
2023-01-25 |
フジフィルム セルラー ダイナミクス,インコーポレイテッド |
多能性幹細胞からhlaホモ接合免疫細胞への指向分化方法
|
WO2018111902A1
(en)
|
2016-12-12 |
2018-06-21 |
Multivir Inc. |
Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
|
WO2018127545A1
(en)
|
2017-01-05 |
2018-07-12 |
Evaxion Biotech Aps |
Vaccines targeting pseudomonas aeruginosa
|
BR112019021745A2
(pt)
|
2017-04-18 |
2020-05-05 |
Fujifilm Cellular Dynamics Inc |
células efetoras imunológicas antígeno-específicas
|
CA3079524A1
(en)
|
2017-11-03 |
2019-05-09 |
Interna Technologies B.V. |
Mirna molecule, equivalent, antagomir, or source thereof for treating and/or diagnosing a condition and/or a disease associated with neuronal deficiency or for neuronal (re)generation
|
US11612618B2
(en)
|
2017-11-14 |
2023-03-28 |
Henry Ford Health System |
Compositions for use in the treatment and prevention of cardiovascular disorders resulting from cerebrovascular injury
|
RU2020124404A
(ru)
|
2018-01-05 |
2022-01-24 |
Оттава Хоспитл Рисерч Инститьют |
Векторы на основе модифицированного вируса осповакцины
|
WO2019145399A1
(en)
|
2018-01-24 |
2019-08-01 |
Evaxion Biotech Aps |
Vaccines for prophylaxis of s. aureus infections
|
KR20200135986A
(ko)
|
2018-03-19 |
2020-12-04 |
멀티비르 인코포레이티드 |
종양 억제인자 유전자 치료 및 cd122/cd132 작용제를 포함하는 암 치료를 위한 방법 및 조성물
|
EP3775214A2
(en)
|
2018-03-30 |
2021-02-17 |
University of Geneva |
Micro rna expression constructs and uses thereof
|
TW202023581A
(zh)
|
2018-08-02 |
2020-07-01 |
日商腫瘤療法 科學股份有限公司 |
來自cdca1的胜肽及含有此的疫苗
|
KR20210102870A
(ko)
|
2018-08-30 |
2021-08-20 |
테나야 테라퓨틱스, 인코포레이티드 |
미오카르딘 및 ascl1을 사용한 심장 세포 재프로그래밍
|
WO2020069313A2
(en)
|
2018-09-28 |
2020-04-02 |
Henry Ford Health System |
Use of extracellular vesicles in combination with tissue plasminogen activator and/or thrombectomy to treat stroke
|
US20220111031A1
(en)
|
2018-10-22 |
2022-04-14 |
Evaxion Biotech Aps |
Vaccines targeting M. catharrhalis
|
US20220098256A1
(en)
|
2018-11-30 |
2022-03-31 |
Tokushima University |
Therapeutic agent for breast cancer comprising big3-phb2 interaction-inhibiting peptide derived from phb2
|
WO2020171889A1
(en)
|
2019-02-19 |
2020-08-27 |
University Of Rochester |
Blocking lipid accumulation or inflammation in thyroid eye disease
|
EP3931206A1
(en)
|
2019-02-27 |
2022-01-05 |
Evaxion Biotech ApS |
Vaccines targeting h. influenzae
|
SG10201905939WA
(en)
|
2019-06-26 |
2021-01-28 |
Cell Mogrify Australia Pty Ltd |
Cell culture methods and compositions
|
EP3997226A1
(en)
|
2019-07-11 |
2022-05-18 |
Tenaya Therapeutics, Inc. |
Cardiac cell reprogramming with micrornas and other factors
|
AU2020317009A1
(en)
|
2019-07-19 |
2022-02-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Chimeric antigen receptors containing Glypican 2 binding domains
|
US20210147525A1
(en)
|
2019-10-18 |
2021-05-20 |
The Regents Of The University Of California |
Methods and compositions for treating pathogenic blood vessel disorders
|
KR102237349B1
(ko)
|
2019-10-23 |
2021-04-07 |
한국과학기술연구원 |
니코틴 중독 또는 금단 증상 예방 또는 치료용 약학 조성물
|
WO2021113644A1
(en)
|
2019-12-05 |
2021-06-10 |
Multivir Inc. |
Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
|
WO2021140123A1
(en)
|
2020-01-06 |
2021-07-15 |
Evaxion Biotech Aps |
Vaccines targeting neisseria gonorrhoeae
|
CA3173567A1
(en)
|
2020-03-02 |
2021-09-10 |
Tenaya Therapeutics, Inc. |
Gene vector control by cardiomyocyte-expressed micrornas
|
US20230211023A1
(en)
|
2020-03-25 |
2023-07-06 |
Erasmus University Medical Center Rotterdam |
Reporter system for radionuclide imaging
|
IL298558A
(en)
|
2020-05-27 |
2023-01-01 |
Antion Biosciences Sa |
Adapter molecules redirect CAR T cells to the antigen of interest
|
EP4157294A1
(en)
|
2020-05-29 |
2023-04-05 |
FUJIFILM Cellular Dynamics, Inc. |
Retinal pigmented epithelium and photoreceptor dual cell aggregates and methods of use thereof
|
BR112022024064A2
(pt)
|
2020-05-29 |
2023-01-31 |
Fujifilm Cellular Dynamics Inc |
Bicamada de epitélio pigmentado da retina e fotorreceptores e uso dos mesmos
|
WO2022053130A1
(en)
|
2020-09-09 |
2022-03-17 |
Sid Alex Group, S.R.O. |
Antago-mir-155 for treatment of v-src, c-src-tyrosine kinase-induced cancers
|
JP2024508088A
(ja)
|
2021-02-09 |
2024-02-22 |
ユニバーシティ オブ ヒューストン システム |
全身送達及び抗腫瘍活性の向上のための腫瘍溶解性ウイルス
|
WO2022175815A1
(en)
|
2021-02-19 |
2022-08-25 |
Pfizer Inc. |
Methods of protecting rna
|
JP2024519218A
(ja)
|
2021-05-03 |
2024-05-09 |
アステラス インスティテュート フォー リジェネレイティブ メディシン |
成熟角膜内皮細胞を作製する方法
|
JP2024518409A
(ja)
|
2021-05-07 |
2024-05-01 |
アステラス インスティテュート フォー リジェネラティブ メディシン |
成熟肝細胞を作製する方法
|
JP2024520413A
(ja)
|
2021-05-26 |
2024-05-24 |
フジフィルム セルラー ダイナミクス,インコーポレイテッド |
多能性幹細胞における遺伝子の迅速なサイレンシングを防止するための方法
|
JP2024526293A
(ja)
|
2021-07-05 |
2024-07-17 |
エヴァクシオン・バイオテック・アクティエセルスカブ |
淋菌を標的とするワクチン
|
WO2023089556A1
(en)
|
2021-11-22 |
2023-05-25 |
Pfizer Inc. |
Reducing risk of antigen mimicry in immunogenic medicaments
|
WO2023144779A1
(en)
|
2022-01-28 |
2023-08-03 |
Pfizer Inc. |
Coronavirus antigen variants
|
CA3242289A1
(en)
|
2022-03-16 |
2023-09-21 |
University Of Houston System |
Persistent hsv gene delivery system
|
GB202205265D0
(en)
|
2022-04-11 |
2022-05-25 |
Mogrify Ltd |
Cell conversion
|
GB202206507D0
(en)
|
2022-05-04 |
2022-06-15 |
Antion Biosciences Sa |
Expression construct
|
WO2023213393A1
(en)
|
2022-05-04 |
2023-11-09 |
Evaxion Biotech A/S |
Staphylococcal protein variants and truncates
|
WO2023239940A1
(en)
|
2022-06-10 |
2023-12-14 |
Research Development Foundation |
Engineered fcriib selective igg1 fc variants and uses thereof
|
WO2024006911A1
(en)
|
2022-06-29 |
2024-01-04 |
FUJIFILM Holdings America Corporation |
Ipsc-derived astrocytes and methods of use thereof
|
WO2024130212A1
(en)
|
2022-12-16 |
2024-06-20 |
Turnstone Biologics Corp. |
Recombinant vaccinia virus encoding one or more natural killer cell and t lymphocyte inhibitors
|